Eiger BioPharmaceuticals, Inc

172 articles about Eiger BioPharmaceuticals, Inc

• Eiger BioPharmaceuticals Announces the Appointment of Stephana Patton as General Counsel, Corporate Secretary, and Chief Compliance Officer

  2/27/2019

  Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced the appointment of Dr. Stephana Patton as the Company's General Counsel, Corporate Secretary, and Chief Compliance Officer. 

• Eiger BioPharmaceuticals Announces Patent Protection for Lonafarnib Boosted with Ritonavir for Treatment of Hepatitis Delta Virus Infection in Europe and Japan

  2/6/2019

  Expanded Patent Portfolio Now Includes U.S., Europe and Japan

• Eiger BioPharmaceuticals Announces Oral Presentation of Phase 2 PREVENT Study of Avexitide in Post-Bariatric Hypoglycemia (PBH) at Upcoming Endocrine Society (ENDO) Meeting 2019 in New Orleans

  2/4/2019

  Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced an oral presentation has been granted for results of the Phase 2 PREVENT study at ENDO 2019 in New Orleans on March 25, 2019. 

• Eiger Announces Breakthrough Therapy Designation Granted by FDA for Lonafarnib in Progeria and Progeroid Laminopathies

  12/19/2018

  Eiger BioPharmaceuticals, Inc (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced that the Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for lonafarnib for the treatment of Hutchinson-Gilford progeria syndrome (HGPS or Progeria) and progeroid laminopathies.

• Eiger Announces Breakthrough Therapy Designation Granted by FDA for Lonafarnib for Treatment of Hepatitis Delta Virus (HDV) Infection

  12/17/2018

  Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced that the Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for lonafarnib for the treatment of hepatitis delta virus (HDV) infection

• Eiger BioPharmaceuticals Reports on 2018 R&D Day

  12/11/2018

   Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced recent accomplishments reported at its R&D Day at the St. Regis Hotel in New York City. 

• Eiger BioPharmaceuticals to Host R&D Day in New York City on December 11, 2018

  12/4/2018

  Eiger BioPharmaceuticals, Inc. today announced it will host an R&D Day on December 11, 2018 from 12:00 PM to 2:30 PM EST at the St. Regis Hotel in New York City. 

• Eiger BioPharmaceuticals Announces the Appointment of Sri Ryali as Chief Financial Officer

  12/3/2018

  Eiger BioPharmaceuticals, Inc. today announced the appointment of Sri Ryali as the company's Chief Financial Officer. 

• Eiger BioPharmaceuticals Announces FDA Acceptance of IND Application for Lonafarnib for the Treatment of Progeria and Progeroid Laminopathies

  12/3/2018

  Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for lonafarnib

• Eiger to Participate in Piper Jaffray Healthcare Conference

  11/19/2018

  Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced that David Cory, President and CEO, will present a corporate update at the 30th Annual Piper Jaffray Healthcare Conference

• Eiger Bio Reports Third Quarter 2018 Financial Results

  11/9/2018

   Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today financial results for the three and nine months ended September 30, 2018 and provided a business update.

• Eiger BioPharmaceuticals Prices Previously Announced Public Offering of Common Stock of $10.35 Per Share

  10/23/2018

  Eiger BioPharmaceuticals, Inc. announced today the pricing of its previously announced underwritten public offering.

• Eiger BioPharmaceuticals Receives FDA Rare Pediatric Disease (RPD) Designation for Lonafarnib for the Treatment of Progeria and Progeroid Laminopathies and Plans NDA Filing in 2019

  10/22/2018

  Designation Enables Priority Review Voucher Eligibility Upon NDA Approval

• Eiger BioPharmaceuticals Announces Positive Phase 2 LIMT Study End of Treatment Data with Pegylated Interferon Lambda Monotherapy in Hepatitis Delta Virus (HDV) Infection

  10/17/2018

  Lambda Antiviral Activity Demonstrated in HDV Infection

• Eiger BioPharmaceuticals Announces Positive Results in Phase 2 PREVENT Study of Avexitide Targeting GLP-1 in Post-Bariatric Hypoglycemia (PBH)

  10/16/2018

  Primary and Secondary Endpoints Achieved with Statistical Significance

• Eiger BioPharmaceuticals Announces Phase 2 ULTRA Results of Ubenimex in Lower Leg Lymphedema: Study Did Not Meet Primary or Secondary Endpoint

  10/16/2018

  Eiger BioPharmaceuticals, Inc. today announced Phase 2 ULTRA study results in primary and secondary lymphedema of the lower limb demonstrated no improvement of ubenimex over placebo in the primary endpoint of skin thickness and secondary endpoints of limb volume and bioimpedance.  No safety signals attributed to ubenimex were identified.

• Eiger BioPharmaceuticals to Participate in October 2018 Investor Conferences

  9/25/2018

  Eiger BioPharmaceuticals, Inc. today announced that David Cory, President and CEO, will present at two investor conferences in October in New York City.

• Eiger BioPharmaceuticals to Participate in September 2018 Investor Conferences

  8/27/2018

  Eiger BioPharmaceuticals, Inc. announced today that members of the Eiger management team will participate in multiple investor conferences in September in New York City.

• Eiger BioPharmaceuticals Announces Completion of Enrollment in Phase 2 PREVENT Study of Avexitide (formerly Exendin 9-39) in Patients Suffering from Post-Bariatric Hypoglycemia

  8/13/2018

  A total of 18 patients were enrolled across five study sites in the United States.

• Eiger BioPharmaceuticals Reports Second Quarter 2018 Financial Results

  8/10/2018

  Eiger BioPharmaceuticals, Inc. announced today financial results for the three and six months ended June 30, 2018 and provided a business update.